Q2 Earnings Forecast for Medifast Issued By Zacks Research

Medifast, Inc. (NYSE:MED) – Equities researchers at Zacks Research reduced their Q2 2025 EPS estimates for shares of Medifast in a research note issued on Monday, March 10th. Zacks Research analyst R. Department now forecasts that the specialty retailer will earn $0.24 per share for the quarter, down from their prior forecast of $0.29. The consensus estimate for Medifast’s current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast’s Q3 2025 earnings at $0.33 EPS, Q1 2026 earnings at $0.32 EPS, Q2 2026 earnings at $0.32 EPS, FY2026 earnings at $1.52 EPS and FY2027 earnings at $2.08 EPS.

Medifast (NYSE:MED) last announced its earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.16) by $0.26. The business had revenue of $119.00 million during the quarter, compared to the consensus estimate of $114.25 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%.

Separately, DA Davidson lowered their target price on Medifast from $17.00 to $16.50 and set a “neutral” rating for the company in a research note on Wednesday, February 19th.

Medifast Price Performance

MED opened at $14.32 on Wednesday. The company has a market capitalization of $156.63 million, a PE ratio of 79.56 and a beta of 1.13. Medifast has a fifty-two week low of $13.57 and a fifty-two week high of $39.14. The business has a 50-day moving average of $15.39 and a 200-day moving average of $17.48.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Prescott Group Capital Management L.L.C. acquired a new stake in Medifast in the 4th quarter worth about $1,938,000. Marshall Wace LLP acquired a new position in Medifast during the 4th quarter worth about $1,836,000. Two Sigma Advisers LP lifted its holdings in Medifast by 86.0% during the 4th quarter. Two Sigma Advisers LP now owns 216,000 shares of the specialty retailer’s stock worth $3,806,000 after buying an additional 99,900 shares during the period. Federated Hermes Inc. raised its position in shares of Medifast by 28.8% in the 4th quarter. Federated Hermes Inc. now owns 279,473 shares of the specialty retailer’s stock worth $4,924,000 after acquiring an additional 62,574 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Medifast by 103.9% in the 4th quarter. JPMorgan Chase & Co. now owns 117,157 shares of the specialty retailer’s stock valued at $2,064,000 after buying an additional 59,702 shares in the last quarter. Institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.